Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation in CD22+ B-cell ALL
NCT02577094Phase 2Withdrawn
- Sponsor
- CHU de Nantes
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of 90Y-epratuzumab tetraxetan in acute lymphoblastic leukemia (ALL), sponsored by CHU de Nantes. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Status: withdrawn.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02577094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577094.